A G Azarova studies how well the medication Revelise (alteplase) helps patients who have experienced ischemic strokes, which occur when blood flow to the brain is blocked. Specifically, their research examines the real-life outcomes of patients receiving this treatment, including how it affects their recovery and reduces disabilities after the stroke. By analyzing data from a significant number of patients, they provide insights into how effective this treatment can be for a variety of individuals, particularly older patients and those with pre-existing health conditions.
Key findings
In a study of 2,202 patients, nearly half (49.9%) had good outcomes at discharge after receiving Revelise for ischemic stroke.
The percentage of patients showing good outcomes increased to 66.4% after 90 days.
Revelise was found to effectively reduce stroke-related disabilities for patients with varying health statuses.
Frequently asked questions
Does Dr. Azarova study ischemic strokes?
Yes, Dr. Azarova specializes in researching treatments for ischemic strokes.
What treatments has Dr. Azarova researched?
Dr. Azarova has primarily researched the effectiveness of the medication Revelise (alteplase) for treating ischemic strokes.
Is Dr. Azarova's work relevant to older patients?
Yes, Dr. Azarova's research includes older patients, demonstrating the medication's effectiveness for individuals with additional health issues.
Publications in plain English
[Increasing the accessibility of reperfusion therapy for ischemic stroke in primary vascular units using teleconsulting in the Russian Federation].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Plain English This study looked at how using teleconsulting in primary vascular units (tele-PVUs) improved access to specialized stroke treatment in Russia. It found that 9.8% of stroke patients treated in these units received thrombolytic therapy, which is higher than the national average, and the time from when symptoms started to when treatment began was also reduced. This is important because it means more patients in rural areas can get life-saving treatment faster.
Who this helps: Patients in rural areas who suffer from ischemic strokes.
[Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Marskaya NA, Khasanova DR +92 more
Plain English This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options.
Who this helps: Patients with acute ischemic stroke and their healthcare providers.
[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more
Plain English This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues.
Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.